The massive dilution (warrants for ~9.4M shares vs. a ~$2M market cap) and distressed pricing signal a high probability of further downside. Traders should monitor for the stockholder approval meeting (required within 75 days) and any subsequent registration statement filing, which could trigger additional selling pressure from warrant exercises.
Price Chart
Executive Summary
VivoSim Labs raised ~$4M in a private placement via the sale of pre-funded warrants (4,705,883 shares at $0.001 exercise price) and common warrants (4,705,883 shares at $0.85 exercise price) to a single institutional investor. The company also amended existing Armistice Capital warrants (520,833 shares) to reduce the exercise price to $0.85 and extend the term. This dilutive capital raise at a $2M market cap signals acute cash needs for working capital, with no disclosed revenue or operational catalyst to offset the dilution. The combination of a dilutive PIPE, warrant repricing, and a micro-cap biotech with no analyst support is bearish.
Key Financial Metrics
Key Facts
- Gross proceeds of ~$4M from sale of 4,705,883 pre-funded warrants (exercise price $0.001) and 4,705,883 common warrants (exercise price $0.85).
- Common warrants exercisable only after stockholder approval, with a 5-year term; pre-funded warrants exercisable immediately.
- Existing Armistice Capital warrants (520,883 shares) amended to reduce exercise price from $9.60 to $0.85 and extend term to 5 years post-stockholder approval.
- Placement agent A.G.P./Alliance Global Partners receives 6.50% cash fee on gross proceeds.
- Market cap is ~$2M; analyst consensus is 0% bullish (4 Hold, 1 Sell, 2 Strong Sell).
- Company intends to use proceeds for working capital and general corporate purposes.
- 60-day lock-up on further equity issuances after registration statement effectiveness; 6-month ban on variable-rate transactions.
Financial Impact
~$4M gross proceeds raised at a ~$2M market cap, representing ~200%+ dilution to existing common shareholders when warrants are exercised. The Armistice warrant repricing from $9.60 to $0.85 effectively transfers significant value to that holder at the expense of existing shareholders.
Risk Factors
- Warrant exercises could flood the market with shares, further depressing the stock price.
- The company may need additional capital beyond this $4M raise, leading to further dilution.
- Failure to obtain stockholder approval for the common warrants could trigger adverse consequences.
- The Armistice warrant amendment at a deeply discounted price suggests potential for further insider-favorable transactions.
- Nasdaq listing requirements may be at risk given the low market cap and potential for continued price declines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-306849 |
| Document: d134319dex42.htm | 0001193125-26-306849 |
| Document: d134319dex41.htm | 0001193125-26-306849 |
| Document: d134319dex102.htm | 0001193125-26-306849 |
| Document: d134319d8k.htm | 0001193125-26-306849 |
| Document: d134319dex43.htm | 0001193125-26-306849 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 8-K | $0.1575 $0.1520 | ▲ +3.49% | ▲ +3.35% | $0.1500 (+4.76%) |
Oct 6, 2026 21d ago | 8-K | $0.1915 $0.1609 | ▼ −15.98% | ▼ −15.00% | $0.1500 (−21.67%) |
Sep 16, 2026 5w ago | Press Release | $0.2621 $0.2291 | ▼ −12.59% | ▼ −15.15% | $0.1500 (−42.77%) |
Aug 11, 2026 11w ago | EFFECT | $0.3526 $0.2786 | ▲ +20.99% | ▲ +20.58% | $0.1500 (+57.46%) |
Aug 6, 2026 11w ago | 8-K | $0.3299 $0.3281 | ▼ −0.55% | ▼ −1.76% | $0.1500 (−54.53%) |
Jul 17, 2026 14w ago | 8-K | $0.5790 $0.4500 | ▲ +22.28% | ▲ +21.59% | $0.1500 (+74.09%) |
Apr 3, 2026 29w ago | 8-K | $1.71 $1.44 | ▼ −15.79% | ▼ −19.92% | $0.1500 (−91.23%) |
Apr 1, 2026 29w ago | Press Release | $1.62 $1.53 | ▲ +5.56% | ▲ +9.32% | $0.1500 (+90.74%) |
Apr 1, 2026 29w ago | EFFECT | $1.62 $1.53 | ▼ −5.56% | ▼ −9.32% | $0.1500 (−90.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers